Prothena News and Activities

Presence

Prothena develops medicines for serious diseases with protein misfolding and neurodegeneration. Its services include drug research and clinical development for patients, healthcare providers, and pharmaceutical partners.

Prothena products and services overview:

Drug discovery
Clinical development
Neuroscience therapies
Rare disease therapies

Revenue: ~$10 million

Employees: 180

Headquarters: South San Francisco, United States (USA)

Prothena is one of the...

Prothena is a company listed under the stock ticker PRTA (US).

Executives

View the org chart displaying its 13 main executives

Most searched biographies at Prothena

Popular executive movements at Prothena

Paula Cobb, Director, has left the company (posted on December 15 2025).

Create your alert
to follow the executive moves at Prothena.

Biotechnology

Prothena has 2,415 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Vertex Pharmaceuticals (United States (USA)).

Popular M&A news in Biotechnology

RQ Biotechnology has just announced a $86 Million fundraising (posted on June 24 2026).
Boundless Bio has filed its IPO. Its stock ticker will be AATD. (posted on June 23 2026).
Boundless Bio will change its company name to Serapha Bio on Dec 31, 2026. (posted on June 23 2026).